Aurora Cannabis (TSX:ACB): Is the Stock Price Pullback Complete?

Aurora Cannabis Inc. (TSX:ACB)(NYSE:ACB) dropped nearly 50% from the recent high, but it’s starting to claw back the losses. Is it time to buy this pot stock?

| More on:

Aurora Cannabis (TSX:ACB)(NYSE:ACB) took a big hit when investors sold off most marijuana stocks in recent weeks.

The past few sessions, however, have been more favourable, and investors who are sitting on the sidelines are wondering if this is the right time to step in and buy Aurora Cannabis stock for their pot stock portfolios.

Let’s take a look at one of Canada’s largest players in the cannabis sector to see if it deserves to be on your buy list.

Growth

Aurora Cannabis has taken an aggressive approach to consolidating the Canadian medical marijuana industry. The company bought CanniMed for $1.1 billion in January in a deal that added important production capacity as well as research and development expertise. In July, Aurora Cannabis closed its $2.5 billion takeover of MedReleaf. The acquisition brought a large client list of medical marijuana patients and further expanded production capacity as well as the portfolio of recognized brands.

With a current market capitalization of more than $9 billion, Aurora Cannabis has the size to make additional moves in its bid to compete with larger peers Canopy Growth and Tilray as the Canadian and global markets expand.

Opportunities?

A number of smaller players might be attractive, but HEXO could be the one that Aurora Cannabis targets. HEXO has a dominant position in Quebec and is already working to enter the cannabis-infused drinks market through its partnership with Molson Coors Canada.

Rumours have emerged that Aurora Cannabis might be in talks with potential beverage partners, but acquiring HEXO could be a way to get instant access to the segment. HEXO has a market capitalization of about $1.3 billion.

A larger deal would be a takeover of Aphria. In that case, Aurora would become a giant in the medical cannabis space in both Canada and abroad. Aphria’s current market capitalization is about $4 billion.

Risks

Despite the plunge in the stock price from $15 per share on October 15 to the October 29th closing price of $7.70, the stock still looks expensive. Current annualized revenue is less than $80 million.

The entire sector is in the same boat, so investors just have to be careful when deciding how much exposure they want to have to the marijuana industry.

Should you buy?

At the time of writing, Aurora Cannabis has a stock price of $10 per share. Investors who had the courage to step in at $8 are already sitting on some nice gains, and more upside could certainly be on the way. As one of the larger players, there isn’t much chance of getting a big takeover premium. That said, any news of a major investment from a beverage giant could send the stock back toward the recent highs.

Aurora Cannabis will likely be one of the few companies that survives the consolidation process to dominate the global medical marijuana market. If you like the industry’s long-term prospects and have the stomach for additional volatility, the stock might be attractive today.

Otherwise, there are additional ways to play the emerging marijuana market.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Andrew Walker has no position in any stock mentioned. The Motley Fool owns shares of Molson Coors Brewing.

More on Investing

Canada national flag waving in wind on clear day
Tech Stocks

Trump Trade: Canadian Stocks to Watch

With Trump returning to the presidency, there are some sectors that could boom in Canada, and others to watch. But…

Read more »

A train passes Morant's curve in Banff National Park in the Canadian Rockies.
Investing

Is Canadian National Railway Worth Buying for its 2.2% Dividend Yield?

Let's dive into whether Canadian National Railway (TSX:CNR) is a top buy for long-term investors at this point in the…

Read more »

nuclear power plant
Energy Stocks

Is Cameco Stock Still a Buy?

Cameco stock recently reported earnings that showed the Westinghouse investment is creating some major costs. But that could change.

Read more »

cloud computing
Dividend Stocks

Insurance Showdown: Better Buy, Great-West Life or Manulife Stock?

GWO stock and MFC stock are two of the top names in insurance, but which holds the better outlook?

Read more »

analyze data
Dividend Stocks

Here’s Why the Average TFSA for Canadians Aged 41 Isn’t Enough

The average TFSA simply isn't enough for most Canadians in their early 40s. Here's how to catch up.

Read more »

A plant grows from coins.
Dividend Stocks

The Smartest Dividend-Growth Stocks to Buy With $1,000 Right Now

New dividend-growth investors should consider CN Rail (TSX:CNR) stock and another top play if they're looking to build wealth over…

Read more »

concept of real estate evaluation
Dividend Stocks

How to Earn a TFSA Paycheque Every Month and Pay No Taxes on It

Canadian REITs can turn your TFSA into a monthly paycheque machine for life. Here's how Morguard North American Residential REIT…

Read more »

Start line on the highway
Investing

2 No-Brainer Growth Stocks to Buy Now With $5,000 and Hold Long Term

Market conditions today are ideal for growth investing, and two rising stocks are no-brainer buys in November.

Read more »